Trastuzumab for gastric cancer

Bibliography

• American Cancer Society: Cancer Facts and Figures 2008. Atlanta, GA: American Cancer Society, 2008. Available from: http://www.cancer.org/docroot/stt/content/stt_1x_cancer_facts_and_figures_2008.asp [Last accessed 22 October 2009]
   Google Scholar
• Sugano K. Gastric cancer: pathogenesis, screening and treatment. Gastrointest Endocopy Clin N Am 2008;18:513-22
   PubMedGoogle Scholar
• Inoue M, Tsugane S. Epidemiology of gastric cancer in Japan. Postgrad Med J 2005;81:419-24
   PubMed Web of Science ®Google Scholar
• Foukakis T, Lundell L, Gubanski M, Advances in the treatment of patients with gastric adenocarcinoma. Acta Oncol 2007;46:277-85
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20
   PubMed Web of Science ®Google Scholar
• Macdonald JS, Smalley SR, Benedetti J, Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30
   PubMed Web of Science ®Google Scholar
• Sakuramoto S, Sasako M, Yamaguchi T, Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-20
   PubMed Web of Science ®Google Scholar
• Murad AM, Santiago FF, Petroianu A, Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41
   PubMed Web of Science ®Google Scholar
• Pyrhönen S, Kuitunen T, Nyandoto P, Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91
   PubMed Web of Science ®Google Scholar
• Glimelius B, Ekstrom K, Hoffman K, Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8
   PubMed Web of Science ®Google Scholar
• Janunger KG, Hafström L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 2002;168:597-608
   PubMedGoogle Scholar
• Wagner AD, Grothe W, Haerting J, Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-9
   PubMed Web of Science ®Google Scholar
• Cervantes A, Roselló S, Roda D, The treatment of advanced gastric cancer: current strategies and future perspectives. Ann Oncol 2008;19(5S):103-7
   Google Scholar
• Ross P, Nicolson M, Cunningham D, Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996-2004
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46
   PubMed Web of Science ®Google Scholar
• Van Cutsen E, Moiseyenko VM, Tjulandin S, Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a Report of the V325 Study Group. J Clin Oncol 2006;24:4991-7
   PubMed Web of Science ®Google Scholar
• Ajani JA, Moiseyenko VM, Tjulandin S, Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a Phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007;25:3205-9
   PubMed Web of Science ®Google Scholar
• Ajani JA, Moiseyenko VM, Tjulandin S, Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a Phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007;25:3210-6
   PubMed Web of Science ®Google Scholar
• Bouché O, Raoul JL, Bonnetain F, Randomized multicenter Phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Fé dé ration Francophone de Cancé rologie Digestive Group Study—FFCD 9803. J Clin Oncol 2004;22:4319-28
   PubMed Web of Science ®Google Scholar
• Moehler M, Eimermacher A, Siebler J, Randomized Phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) versus 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005;92:2122-8
   PubMed Web of Science ®Google Scholar
• Dank M, Zaluski J, Valvere V, Randomized Phase III trial of irinotecan (CPT 11) 5- FU/folinic acid (FA) vs CDDP–5-FU in first line advanced gastric cancer patients. J Clin Oncol 2005;23(308S): abstract 4003
   Google Scholar
• Boku N, Yamamoto S, Shirao K, Randomized Phase III study of 5-fl uorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). Annual Meeting ASCO 2007; abstract LBA4513T
   Google Scholar
• Imamura H, IIishi H, Tsuburaya A, Randomized Phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/TOP-002). ASCO Gastrointestinal Symposium 2008; abstract 5
   Google Scholar
• Koizumi W, Narahara H, Hara T, S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a Phase III trial. Lancet Oncol 2008;9:215-21
   PubMed Web of Science ®Google Scholar
• Ajani JA, Rodriguez W, Bodoky G, Multicenter Phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS). ASCO Gastrointestinal Cancers Symposium 2009; abstract 8
   Google Scholar
• Thuss-Patience PC, Kretzschmar A, Deist T, Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized Phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 2009;27(15s): abstract 4540
   Google Scholar
• Wilson D, Hiller L, Geh JI. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol) 2005;17:81-90
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Rigatos SK, Fountzilas G, Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study. Oncol Rep 2002;9:89-92
   PubMed Web of Science ®Google Scholar
• Cascinu S, Graziano F, Cardarelli N, Phase II study of paclitaxel in pre-treated advanced gastric cancer. Anticancer Drugs 1998;9:307-10
   PubMed Web of Science ®Google Scholar
• Boku N. Chemotherapy for metastatic gastric cancer in Japan. Int J Clin Oncol 2008;13:483-7
   PubMed Web of Science ®Google Scholar
• Arkenau HT. Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J Cancer Res Clin Oncol 2009;135:855-66
   Google Scholar
• Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol 2008;43:256-64
   PubMed Web of Science ®Google Scholar
• Shah MA, Ramanathan RK, Ilson DH, Multicenter Phase II study of irinotecan, cisplatin and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:5201-6
   PubMed Web of Science ®Google Scholar
• Enzinger PC, Fidias P, Meyerhardt J, Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. ASCO Gastrointestinal Cancers Symposium 2006; abstract 68
   Google Scholar
• Cohenuram MK, Lacy J. FOLFOX6 and bevacizumab (FOLFOX6/B) for metastatic esophageal (E), gastroesophageal (GE), and gastric (G) adenocarcinoma: a single institution's initial clinical experience. Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL, USA, 2008; abstract 74
   Google Scholar
• Hammad N, Philip PA, Shields AF, A Phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and gastroesophageal junction (GEJ) cancer. Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL, USA, 2008; abstract 30
   Google Scholar
• Bang YJ, Kang Y, Kang W, Sunitinib as second line treatment for advanced gastric cancer: preliminary results from a Phase II study. J Clin Oncol 2007;25(18S): abstract 4603
   Google Scholar
• Sun W, Powell ME, O'Dwyer P, A Phase II study: combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203). J Clin Oncol 2008;26:4535
   PubMedGoogle Scholar
• Stein A, Al-Batran SE, Arnold D, Cetuximab with irinotecan as salvage therapy in heavily pretreated patients with metastatic gastric cancer. Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL, USA, 2007; abstract 47
   Google Scholar
• Pinto C, Di Fabio F, Siena S, Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007;18:510-7
   PubMed Web of Science ®Google Scholar
• Lordick F, Lorenzen S, Hegewisch-Becker S, Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter Phase II study of the AIO upper GI study group. J Clin Oncol 2007;25(18S): abstract 4526
   PubMedGoogle Scholar
• Woell E, Greil R, Eisterer W, Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer: first results of a multicenter Phase II trial (AGMT Gastric-2). J Clin Oncol 2008;26:15587
   Google Scholar
• Tebbutt NC, Sourjina T, Strickland AH, ATTAX2: docetaxel plus cetuximab as second-line treatment for docetaxelrefractory oesophago-gastric cancer–final results of a multicentre Phase II trial by the AGITG. J Clin Oncol 2008;26(20S): abstract 15554
   Google Scholar
• Rao S, Starling N, Benson M, Phase I study of the humanized epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with ECX (epirubicin, cisplatin and capecitabine) as first line treatment for advanced oesophagogastric (OG) adenocarcinoma. J Clin Oncol 2005;23(16S): abstract 4028
   Google Scholar
• Dragovich T, McCoy S, Fenoglio-Preiser C, SWOG 0127 Phase II trial of erlotinib in GEJ and gastric adenocarcinoma. J Clin Oncol 2006;24:4922-7
   PubMed Web of Science ®Google Scholar
• Doi T, Koizumi W, Siena S, Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc Am Soc Clin Oncol 2003;22: abstract 1036
   Google Scholar
• Iqbal S, Goldman B, Lenz HJ, A Phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer. J Clin Oncol 2007;25(18S): abstract 4621
   Google Scholar
• Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-75
   PubMed Web of Science ®Google Scholar
• Halla PS, Cameron DA. Current perspective – Trastuzumab. Eur J Cancer 2009;45(1):12-8
   PubMed Web of Science ®Google Scholar
• Carter P, Presta L, Gorman CM, Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89:4285-9
   PubMed Web of Science ®Google Scholar
• Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007;18:977-84
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D, Randomized Phase II trial of the efficacy and safety of Trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84
   PubMed Web of Science ®Google Scholar
• Smith I, Procter M, Gelber RD, HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36
   PubMed Web of Science ®Google Scholar
• Treish I, Schwartz R, Lindley C. Pharmacology and therapeutic use of trastuzumab in breast cancer. Am J Health Syst Pharm 2000;57:2063-76
   PubMed Web of Science ®Google Scholar
• Bruno R, Washington CB, Lu JF, Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 2005;56:361-9
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B, Gelmon K, Ayoub JP, Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003;21:3965-71
   PubMed Web of Science ®Google Scholar
• Baselga J, Carbonell X, Castañeda-Soto NJ, Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23:2162-71
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51
   PubMed Web of Science ®Google Scholar
• Seidman A, Hudis C, Pierri MK, Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-21
   PubMed Web of Science ®Google Scholar
• González V, Salgueiro E, Jimeno FJ, Post-marketing safety of antineoplasic monoclonal antibodies: rituximab and trastuzumab. Pharmacoepidemiol Drug Saf 2008;17:714-21
   PubMed Web of Science ®Google Scholar
• Marx AH, Tharun L, Muth J, HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009;40:769-7
   PubMed Web of Science ®Google Scholar
• Barros-Silva JD, Leitão D, Afonso L, Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009;100:487-93
   PubMed Web of Science ®Google Scholar
• Kim MA, Jung EJ, Lee HS, Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 2007;38:1386-93
   PubMed Web of Science ®Google Scholar
• Tanner M, Hollmen M, Junttila TT, Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-8
   PubMed Web of Science ®Google Scholar
• Yano T, Doi T, Ohtsu A, Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006;15:65-71
   PubMed Web of Science ®Google Scholar
• Yu GZ, Chen Y, Wang JJ. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol 2009;135(10):1331-9
   PubMed Web of Science ®Google Scholar
• Bang Y, Chung H, Xu J, Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 2009;27(15S): abstract 4556
   Google Scholar
• Gong SJ, Jin CJ, Rha SY, Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett 2004;214:215-24
   PubMed Web of Science ®Google Scholar
• Cortés-Funes H, Rivera F, Alés I, Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/ amplification. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(18s): abstract 4613
   Google Scholar
• Van Cutsem E, Kang Y, Chung H, Efficacy results from the ToGA trial: A Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009;27(18s): abstract LBA4509
   Google Scholar